UBA3

NEDD8-activating enzyme E1 catalytic subunit

6,803 patent compounds predicted against UBA3, 4,795 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL782478	1.00	20/20
SCHEMBL782622	1.00	20/20
SCHEMBL782657	1.00	20/20
SCHEMBL782697	1.00	20/20
SCHEMBL782713	1.00	20/20
SCHEMBL782727	1.00	20/20
SCHEMBL782736	1.00	20/20
SCHEMBL782768	1.00	20/20
SCHEMBL782791	1.00	20/20
SCHEMBL782870	1.00	20/20
SCHEMBL782888	1.00	20/20
SCHEMBL783481	1.00	20/20
SCHEMBL783604	1.00	20/20
SCHEMBL783611	1.00	20/20
SCHEMBL783653	1.00	20/20
SCHEMBL789213	1.00	20/20
SCHEMBL783523	0.80	20/20
SCHEMBL805370	0.79	20/20
SCHEMBL782876	0.78	20/20
SCHEMBL802413	0.78	20/20

Germline variants in UBA3 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full UBA3 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to UBA3 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitors on Sarcopenia in Hemodialysis Patients	PHASE4	NOT_YET_RECRUITING
To Investigate the Efficacy and Safety of UB-421 Monotherapy in HIV-1 Infected Adults	PHASE3	WITHDRAWN
Olaparib in Patients With HRD Malignant Mesothelioma	PHASE2	RECRUITING
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma	PHASE2	SUSPENDED
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Phase II Study of Vandetanib in Individuals With Kidney Cancer	PHASE2	COMPLETED
A Trial of Anti-CD4 Antibody UB-421 in Combination With Optimized Background Antiretroviral Therapy in Patients With Multi-Drug Resistant HIV-1 Infection	PHASE2	WITHDRAWN
Effect of Deferoxamine on Wound Healing Rate in Patients With Diabetes Foot Ulcers	PHASE2	NOT_YET_RECRUITING
Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy	PHASE2	ACTIVE_NOT_RECRUITING
Desferal Administration to Improve the Impaired Reaction to Hypoxia in Diabetes	PHASE2	UNKNOWN
MLN9708 and Dexamethasone for High-Risk Smoldering Multiple Myeloma	PHASE2	WITHDRAWN
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)	PHASE1	COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck	PHASE1	COMPLETED
Differential Gene Expression of Liver Tissue and Blood From Individuals With Chronic Viral Hepatitis	nan	UNKNOWN
Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1	nan	RECRUITING
Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome	nan	RECRUITING
Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome	nan	RECRUITING
Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors	nan	NOT_YET_RECRUITING
The Role of RING Ubiquitin Ligases in Biologic and Oncologic Processes in Tissues of Mesenchymal Origin	nan	UNKNOWN
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome	nan	RECRUITING
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma	nan	COMPLETED
A Natural History Study of Angelman Syndrome	nan	RECRUITING
Inhibition of SENP1 for the Suppression of OS Growth and Metastasis	nan	UNKNOWN
Establishment of a Prospective Clinical-biological Database	nan	RECRUITING
Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC)	nan	UNKNOWN
Autophagy in Systemic Lupus Erythematosus	nan	UNKNOWN
Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders	nan	RECRUITING
Male breAsT cAncer preDisposition Factor: Creation of a Control Cohort 2	nan	NOT_YET_RECRUITING
Effect of Dietary Nitrate on Immobilization-induced Changes in Skeletal Muscle in Young Healthy Men	nan	RECRUITING
Investigation of Copy Number Variations and Genetic Variants in POI	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a UBA3 binder may also engage these)

Protein	Name	Similarity
Q5R4A0	—	1.000	Q5R4A0 →
Q8C878	—	1.000	Q8C878 →
Q99MI7	—	1.000	Q99MI7 →
Q7ZVX6	—	1.000	Q7ZVX6 →
Q9Z1F9	—	0.989	Q9Z1F9 →
UBA2	SUMO-activating enzyme subunit 2	0.986	landscape →
Q7ZY60	—	0.983	Q7ZY60 →
Q642Q1	—	0.981	Q642Q1 →
Q28GH3	—	0.977	Q28GH3 →
Q7SXG4	—	0.973	Q7SXG4 →
A3KMV5	—	0.973	A3KMV5 →
Q5U300	—	0.971	Q5U300 →
Q5ZKY2	—	0.970	Q5ZKY2 →
Q641Y5	—	0.970	Q641Y5 →
Q02053	—	0.970	Q02053 →
Q6IQS6	—	0.970	Q6IQS6 →
Q5R8R4	—	0.969	Q5R8R4 →
Q8BMF3	—	0.969	Q8BMF3 →
Q28DS0	—	0.968	Q28DS0 →
Q9V6U8	—	0.968	Q9V6U8 →
ME3	NADP-dependent malic enzyme, mitochondrial	0.967	landscape →
UBA1	Ubiquitin-like modifier-activating enzyme 1	0.967	landscape →
Q5RGJ5	—	0.967	Q5RGJ5 →
Q64514	—	0.967	Q64514 →
ATG7	Ubiquitin-like modifier-activating enzyme ATG7	0.966	landscape →
Q5EA88	—	0.966	Q5EA88 →
A0A1F3	—	0.966	A0A1F3 →
Q29504	—	0.966	Q29504 →
Q9VE51	—	0.966	Q9VE51 →
P00337	—	0.965	P00337 →